2014
Adjuvant Chemotherapy in Breast Cancer
Lim E, Goel S, Winer E. Adjuvant Chemotherapy in Breast Cancer. 2014, 335-351. DOI: 10.1007/978-1-4939-1145-5_23.Peer-Reviewed Original ResearchAdjuvant chemotherapyAdjuvant chemotherapy regimenAdjuvant systemic therapyAdjuvant combination chemotherapyBreast cancer recurrenceYears of ageChemotherapy regimenPrognostic determinantsSystemic therapyCombination chemotherapyClinicians' estimationTumor stagePatient prognosisPatient outcomesCancer recurrenceBreast cancerMortality rateClinical practiceTumor biologyClinical settingChemotherapyBiological rationalePrognosisRecurrenceSignificant reduction
2011
OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.
Mayer E, Ligibel J, Burstein H, Peppercorn J, Miller K, Carey L, Dickler M, Mayer I, Forero A, Eng-Wong J, Pletcher P, Ryabin N, Gelman R, Wolff A, Winer E. OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. Cancer Research 2011, 71: ot3-02-04-ot3-02-04. DOI: 10.1158/0008-5472.sabcs11-ot3-02-04.Peer-Reviewed Original ResearchPreoperative chemotherapyBreast cancerLifestyle interventionPhase II Randomized StudyAcceptable organ functionResidual invasive diseaseAdjuvant combination chemotherapyTaxane-based chemotherapyRecurrence-free survivalResidual breast cancerRisk of recurrenceFuture clinical trialsStructured exercise programImpact of exerciseAnti-angiogenic agentsUnmet medical needContribution of exerciseQuality of lifeYear BAdjuvant bevacizumabDFCI 05Eligible ptsLast surgeryNeoadjuvant chemotherapyPrimary endpoint